Blog - Page 842 of 5706 - QualityStocks

MondayNov 21, 2022 12:22 pm

QualityStocksNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue, with initial data expected during the first quarter of 2023. “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where…

MondayNov 21, 2022 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform

BEAT named winner of the 2022 Cardiovascular Innovations (“CVI”) Innovation Summit and Shark Tank Competition Company’s presentation included an overview of its HeartBeam AIMI™ platform, which aids in more precise heart attack diagnosis HeartBeam is building an intellectual-property portfolio focused on enabling 12-lead electrocardiogram (“ECG”) diagnostics outside of a medical setting HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been named winner of the annual Cardiovascular Innovations (“CVI”) 2022 Innovation Summit and Shark Tank Competition (https://ibn.fm/ftaNr). The annual conference focuses on innovative health solutions…

MondayNov 21, 2022 11:31 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Schedules Q3 2022 Earnings Call

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that it will host its third quarter 2022 earnings call via webcast at 4:30 p.m. ET on Monday, Nov. 28. During the webcast, Flora management will deliver financial and operational results for the third quarter ended Sept. 30, 2022, and provide updates on the company’s commercial wholesale operations, house of brands and life sciences division strategies. Following the presentation, Flora management will open the call to analysts, media and investors in a Q&A format. Interested parties should visit https://ibn.fm/j1zip to register for…

MondayNov 21, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growth Agreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020 Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it…

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetes The company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetes Lexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertension So far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build…

MondayNov 21, 2022 9:00 am

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) is Powering a Clean Energy Future with Carbon-Negative RNG

RNG is considered carbon-neutral because it is derived from organic sources that produce methane emissions while decaying EverGen is developing Canadian RNG infrastructure with projects in British Columbia, Alberta, and Ontario EverGen’s expansion projects backed by Canada’s highly regulated energy sector, supported with long-term contracted revenue agreements According to the United Nations, the future of clean energy depends on fuel sources that are economical and reliable while minimizing carbon emissions (https://ibn.fm/NSl40). Sources with a minimal or zero carbon footprint like liquified natural gas (“LNG”), solar panels, and wind turbines are viable options, however renewable natural gas (“RNG”) provides a stronger…

FridayNov 18, 2022 3:42 pm

QualityStocksNewsBreaks – GeoSolar Technologies Inc.’s SmartGreen(TM) Is Total Building Energy ‘Makeover’

GeoSolar Technologies is a Colorado-based company dedicated to Net-Zero initiatives by helping residents and businesses reduce carbon emissions and achieve energy independence. “The company’s SmartGreen(TM) Home systems harness the power of the sun and earth to heat and cool buildings, charge electric vehicles, and run electric appliances while purifying the air and maximizing energy efficiency… With an eye on global Net-Zero goals, GeoSolar’s technology empowers building owners to act locally by leveraging a mix of renewable energy sources. The company’s patent pending SmartGreen(TM) Home system is a total building energy ‘makeover’ that comprises solar panels and geothermal ground loops to…

FridayNov 18, 2022 3:01 pm

QualityStocksNewsBreaks – REZYFi Inc. Leading Industry with Diversified Approach to Real Estate Lending Sector

REZYFi, a growth mortgage origination and specialized financing company servicing the needs of both traditional and non-traditional consumers and businesses, is uniquely positioned as the first cannabis mortgage banker in the United States. “REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac, Inc. REZYFi Lending leverages a wide network to offer options such as 15- to 30-year fixed-rate, FHA, VA, and jumbo loans and reverse and adjustable-rate mortgages. The company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the company’s launch of a high-margin…

FridayNov 18, 2022 12:29 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability…

Site Search

Company Search